Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial

This study aimed to improve neoadjuvant therapy for patients with locally advanced rectal cancer with the radiosensitizer trifluridine/tipiracil and monitoring of residual disease with circulating tumor DNA. The combination was tolerable and effective, with 2 complete responses and downstaging in 8 of 9 patients. Our findings underline the potential and limitations of liquid biopsy in order to potentially guide treatment decisions. Background: Optimizing functional outcomes and securing long-term remissions are key goals in managing patients with locally advanced rectal cancer. In this proof-of-concept study, we set out to further optimize neoadjuvant therapy by integrating the radiosensitizer tr iflur idine/tipiracil and explore the potential of cell free tumor DNA (ctDNA) to monitor residual disease. Methods: About 10 patients were enrolled in the phase I dose finding part which followed a 3 + 3 dose escalation design. Tipiracil/tr iflur idine was administered concomitantly to radiotherapy. ctDNA monitoring was performed before and after chemoradiation with patient-individualized digital droplet PCRs. Results: No dose-limiting toxicities were observed at the maximum tolerated dose level of 2 x 35 mg/m 2 tr iflur idine/tipiracil. There were 9 grade 3 adverse events, of which 8 were hematologic with anemia and leukopenia. Chemoradiation yielded a pathological complete response in 1 out of 8 assessable patients, downstaging in nearly all patients, and 1 clinical complete response referred for watchful waiting. Three of 4 assessable patients with residual tumor cells at pathological assessment remained liquid biopsy positive after chemoradiation, but 1 turned negative. Conclusion: In this exploratory phase I trial, the novel combination of neoadjuvant tr iflur idine/tipiracil and radiotherapy proved to be feasible, tolerable, and effective. However, the application of liquid biopsy as a potential marker for therapeutic de-escalation in the neoadjuvant setting requires additional research and prospective validation. The trial was registered at ClinicalTrials.gov: NCT04177602.